Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
TiumBio Files for Phase 1b Trial of Prolonged-Action rFVIIa TU7710 in Hemophilia Patients
Pharma Pioneer
3 min read
TiumBio Files for Phase 1b Trial of Prolonged-Action rFVIIa TU7710 in Hemophilia Patients
19 May 2024
This submission is for a Phase 1b clinical trial of TU7710, a novel recombinant activated factor VII (rFVIIa), intended to treat hemophilia A or B patients with inhibitors.
Read →
Opus Genetics Completes Dosing in Phase 1/2 Gene Therapy Trial for Inherited Retinal Dystrophy LCA5
Pharma Pioneer
2 min read
Opus Genetics Completes Dosing in Phase 1/2 Gene Therapy Trial for Inherited Retinal Dystrophy LCA5
19 May 2024
Opus Genetics reported positive results from its Phase 1/2 clinical trial. The trial is testing OPGx-LCA5.
Read →
Positive Early-Stage Results for Stoke's Genetic Epilepsy Therapy Boost Stock
Pharma Pioneer
3 min read
Positive Early-Stage Results for Stoke's Genetic Epilepsy Therapy Boost Stock
19 May 2024
Stoke Therapeutics has announced encouraging results from its Phase I/IIa clinical trial for a treatment candidate, STK-001, for Dravet syndrome.
Read →
Promising Phase I Results for Viking's Obesity Pill VK2735
Pharma Pioneer
2 min read
Promising Phase I Results for Viking's Obesity Pill VK2735
19 May 2024
Viking Therapeutics has announced positive results from a Phase I clinical trial of VK2735, an oral medication for obesity.
Read →
FSD Pharma Partners with iNGENu CRO for Lucid-MS Clinical Safety and Pharmacokinetics Study in Adults
Pharma Pioneer
2 min read
FSD Pharma Partners with iNGENu CRO for Lucid-MS Clinical Safety and Pharmacokinetics Study in Adults
19 May 2024
FSD Pharma has announced the initiation of a Phase 1 clinical trial for a novel compound, Lucid-21-302, intended to treat multiple sclerosis (MS).
Read →
Cantargia Announces Advances in DOD-Funded Leukemia Clinical Trial for Nadunolimab
Pharma Pioneer
3 min read
Cantargia Announces Advances in DOD-Funded Leukemia Clinical Trial for Nadunolimab
19 May 2024
Cantargia a drug under investigation for use in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Read →
Sagimet Biosciences Reports Finalized Phase 1 Study on Denifanstat for Liver Dysfunction
Pharma Pioneer
2 min read
Sagimet Biosciences Reports Finalized Phase 1 Study on Denifanstat for Liver Dysfunction
19 May 2024
Sagimet Biosciences a drug candidate aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).
Read →
Iambic Initiates Phase 1 Trial of HER2 Inhibitor IAM1363 for Solid Tumor Treatment
Pharma Pioneer
2 min read
Iambic Initiates Phase 1 Trial of HER2 Inhibitor IAM1363 for Solid Tumor Treatment
19 May 2024
Iambic Therapeutics has dosed the first patient in a Phase 1 clinical trial for IAM1363.
Read →
SillaJen Files Clinical Study Report with FDA for REN026 Trial in Renal Cell Carcinoma Patients
Pharma Pioneer
2 min read
SillaJen Files Clinical Study Report with FDA for REN026 Trial in Renal Cell Carcinoma Patients
19 May 2024
This is a phase 1b/2a study that evaluates the safety and efficacy of Pexa-Vec, a modified vaccinia virus, when used alongside cemiplimab, an anti-PD-1 monoclonal antibody from Regeneron Pharmaceuticals Inc.
Read →
Immuneering Commences Phase 1/2a Trial with First Patient Dosed for RAF/RAS Mutated Solid Tumor Treatment
Pharma Pioneer
2 min read
Immuneering Commences Phase 1/2a Trial with First Patient Dosed for RAF/RAS Mutated Solid Tumor Treatment
19 May 2024
Immuneering Corporation, a clinical-stage oncology firm, has initiated a Phase 1/2a clinical trial for IMM-6-415, a novel Deep Cyclic Inhibitor (DCI) targeting the MAPK pathway.
Read →
Affimed N.V. Announces 2023 Financial Outcomes and Corporate Developments
Pharma Pioneer
2 min read
Affimed N.V. Announces 2023 Financial Outcomes and Corporate Developments
19 May 2024
AFM24 Clinical Trial Updates: In a Phase 1/2a study combining AFM24 with atezolizumab for non-small cell lung cancer (NSCLC) patients with EGFR-wildtype.
Read →
VRON-0200 Phase 1B Data Show Promise for Chronic Hepatitis B Functional Cure at 2024 APASL
Pharma Pioneer
3 min read
VRON-0200 Phase 1B Data Show Promise for Chronic Hepatitis B Functional Cure at 2024 APASL
19 May 2024
The preliminary safety findings from a Phase 1B clinical trial involving VRON-0200, a groundbreaking immunotherapy for chronic hepatitis B (HBV), were recently highlighted.
Read →